Frederic Li 25th Lorne Cancer Conference 2013

Abstracts this author is presenting:

• Receptor Tyrosine Kinases differ in their ability to confer resistance to Vemurafenib (PLX4032) treatment in BRAFV600E melanoma. — Poster Session 1